36. Gottesman MM, Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: 385–427. 37. Ihnat MA, Lariviere JP, Warren AJ, La Ronde N, Blaxall JR, et al. (1997) Suppression of P-glycoprotein expression and multidrug resistance by DNA cross-linking agents. Clin Cancer Res 3: 1339–1346. 38. Hamilton JW, McCaffrey J, Caron RM, Louis CA, Treadwell MD, et al. (1994) Genotoxic chemical carcinogens target inducible genes in vivo. Ann N Y Acad Sci 726: 343–345. 39. Mazar AP (2008) Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy. Clin Cancer Res 14: 5649–5655. 40. Kariko K, Kuo A, Boyd D, Okada SS, Cines DB, et al. (1993) Overexpression of urokinase receptor increases matrix invasion without altering cell migration in a human osteosarcoma cell line. Cancer Res 53: 3109–3117. 41. MacEwen EG, Kutzke J, Carew J, Pastor J, Schmidt JA, et al. (2003) c-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells. Clin Exp Metastasis 20: 421–430. 42. MacEwen EG, Pastor J, Kutzke J, Tsan R, Kurzman ID, et al. (2004) IGF-1 receptor contributes to the malignant phenotype in human and canine osteosarcoma. J Cell Biochem 92: 77–91. 43. de Bock CE, Lin Z, Itoh T, Morris D, Murrell G, et al. (2005) Inhibition of urokinase receptor gene expression and cell invasion by anti-uPAR DNAzymes in osteosarcoma cells. Febs J 272: 3572–3582. 44. Dass CR, Nadesapillai AP, Robin D, Howard ML, Fisher JL, et al. (2005) Downregulation of uPAR confirms link in growth and metastasis of osteosarcoma. Clin Exp Metastasis 22: 643–652. 45. Smith HW, Marshall CJ (2010) Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 11: 23–36. 46. Lengyel E, Wang H, Stepp E, Juarez J, Wang Y, et al. (1996) Requirement of an upstream AP-1 motif for the constitutive and phorbol ester-inducible expression Chemotherapy Prevents OS Invasion by EGR1 of the urokinase-type plasminogen activator receptor gene. J Biol Chem 271: 23176–23184. 47. Krishnamachary B, Berg-Dixon S, Kelly B, Agani F, Feldser D, et al. (2003) Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res 63: 1138–1143. 48. Rius J, Guma M, Schachtrup C, Akassoglou K, Zinkernagel AS, et al. (2008) NF-kappaB links innate immunity to the hypoxic response through transcrip- tional regulation of HIF-1alpha. Nature 453: 807–811. 49. Mahalingam D, Mita A, Sankhala K, Swords R, Kelly K, et al. (2009) Targeting sarcomas: novel biological agents and future perspectives. Curr Drug Targets 10: 937–949. 50. Lammers T, Hennink WE, Storm G (2008) Tumour-targeted nanomedicines: principles and practice. Br J Cancer 99: 392–397. 51. Knight ZA, Lin H, Shokat KM (2010) Targeting the cancer kinome through polypharmacology. Nat Rev Cancer 10: 130–137. 52. Zhang J, Yang PL, Gray NS (2009) Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 9: 28–39. 53. Henley DB, May PC, Dean RA, Siemers ER (2009) Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer’s disease. Expert Opin Pharmacother 10: 1657–1664. 54. Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Browning KR, et al. (2009) A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol 66: 48–54. 55. Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, et al. (2008) Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol 65: 1031–1038. 56. Tanaka M, Setoguchi T, Hirotsu M, Gao H, Sasaki H, et al. (2009) Inhibition of Notch pathway prevents osteosarcoma growth by cell cycle regulation. Br J Cancer 100: 1957–1965. PLoS ONE | www.plosone.org 12 January 2011 | Volume 6 | Issue 1 | e16234